COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

VNP40101M and Temozolomide in Treating Patients With Progressive or Relapsed Malignant Glioma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00516282
Recruitment Status : Terminated (The pharmaceutical collaborator filed for bankruptcy and as a result, the study was unable to move into the phase II portion.)
First Posted : August 15, 2007
Last Update Posted : August 26, 2011
Vion Pharmaceuticals
Information provided by (Responsible Party):
Northwestern University

No Study Results Posted on for this Study
Recruitment Status : Terminated
Actual Primary Completion Date : October 2009
Actual Study Completion Date : October 2009